Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × testosterone enanthate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Castration Resistant Metastatic Prostate Cancer 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Fatigue 1 Castration-Resistant Prostate Carcinoma 1 Carcinoma, Squamous Cell 1 Cachexia 1

Interventions

Docetaxel 147 Magnetic Resonance Spectroscopy 122 Radiotherapy 121 Leuprolide 97 Prednisone 94 enzalutamide 90 Radiosurgery 89 Abiraterone Acetate 78 Androgen Antagonists 77 Goserelin 71 bicalutamide 68 gallium 68 PSMA-11 56 Specimen Handling 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 50 Surveys and Questionnaires 50 apalutamide 48 Radiation 42 Biopsy 42 Brachytherapy 39 Gonadotropin-Releasing Hormone 38 Standard of Care 37 abiraterone 35 Blood Specimen Collection 34 darolutamide 33 cabazitaxel 33 Radiotherapy, Intensity-Modulated 32 Exercise 32 Carboplatin 31 Triptorelin Pamoate 28 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06594926 2025-11-26

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡